key: cord-0857900-8o8qz98c
authors: da Silva Costa, Wesla Neves; Miguel, Juliana Padovezi; dos Santos Prado, Fabiana; de Mello Lula, Liz Helena Santos; Junqueira Amarante, Gustavo Adolpho; Righetti, Renato Fraga; Yamaguti, Wellington Pereira
title: Noninvasive ventilation and high-flow nasal cannula in patients with acute hypoxemic respiratory failure by covid-19: a retrospective study of the feasebility, safety and outcomes
date: 2022-01-10
journal: Respir Physiol Neurobiol
DOI: 10.1016/j.resp.2022.103842
sha: 68ed56240c4d069b3c6bc2a4ed3c5711c47100ec
doc_id: 857900
cord_uid: 8o8qz98c

BACKGROUND: Noninvasive ventilation (NIV) and High-flow nasal cannula (HFNC) are the main forms of treatment for acute respiratory failure. This study aimed to evaluate the effect, safety, and applicability of the NIV and HFNC in patients with acute hypoxemic respiratory failure (AHRF) caused by COVID-19. METHODS: In this retrospective study, we monitored the effect of NIV and HFNC on the SpO(2) and respiratory rate before, during, and after treatment, length of stay, rates of endotracheal intubation, and mortality in patients with AHRF caused by COVID-19. Additionally, data regarding RT-PCR from physiotherapists who were directly involved in assisting COVID-19 patients and non-COVID-19. RESULTS: 62.2% of patients were treated with HFNC. ROX index increased during and after NIV and HFNC treatment (P < 0.05). SpO(2) increased during NIV treatment (P < 0.05), but was not maintained after treatment (P = 0.17). In addition, there was no difference in the respiratory rate during or after the NIV (P = 0.95) or HFNC (P = 0.60) treatment. The mortality rate was 35.7% for NIV vs 21.4% for HFNC (P = 0.45), while the total endotracheal intubation rate was 57.1% for NIV vs 69.6% for HFNC (P = 0.49). Two adverse events occurred during treatment with NIV and eight occurred during treatment with HFNC. There was no difference in the physiotherapists who tested positive for SARS-CoV-2 directly involved in assisting COVID-19 patients and non-COVID-19 ones (P = 0.81). CONCLUSION: The application of NIV and HFNC in the critical care unit is feasible and associated with favorable outcomes. In addition, there was no increase in the infection of physiotherapists with SARS-CoV-2.

Coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging viral infection that is rapidly spreading across the globe and three months after the emergence, the World Health Organization declared it a pandemic (World Health Organization, 2020) . Several hospitals needed to prepare and create guidelines for the healthcare team for coping and managing these patients (Lazzeri et al., 2020; Righetti et al., 2020) .

Patients with COVID-19 present several symptoms, such as fever, cough, fatigue, sputum production, and shortness of breath (Huang et al., 2020) . Approximately 14% of patients develop a severe form of COVID-19, requiring hospitalization, and the percentage of patients who required ICU care has varied from 5% to 32% (Huang et al., 2020; Guan et al., 2020; . Older patients and those with chronic underlying conditions can develop severe illness and present complications such as acute hypoxemic respiratory failure (AHRF), acute respiratory disease syndrome J o u r n a l P r e -p r o o f (ARDS), sepsis, septic shock, and kidney and cardiac failure, which require treatment in an intensive care unit (ICU) and supportive respiratory therapy (Yang et al., 2020) .

Noninvasive ventilation (NIV) and high-flow nasal cannula (HFNC) are the main forms of treatment for acute respiratory failure (Spoletini et al., 2016) . Recent guidelines for the respiratory management of SARS-CoV-2 infection suggest the use of the NIV and HFNC also for the treatment of AHRF caused by SARS-CoV-2 unresponsive to conventional oxygen therapy (Lazzeri et al., 2020; Righetti et al., 2020; Alhazzani et al., 2020) . However, data on the safety and applicability of NIV and HFNC in these patients are scarce and there are major concerns on the possibility of spreading infection among healthcare personnel caring for patients in SARS-CoV-2 dedicated areas. The present study aims to evaluate the effect, safety, and applicability of the NIV and HFNC in patients with acute hypoxemic respiratory failure (AHRF) caused by COVID-19.

Hospital Sírio-Libanês (number 3,994,535).

The present study was conducted at a private tertiary hospital (Hospital Sírio- NIV was performed in devices with a heat moisture exchange filter (HMEF) between the face mask or total face mask and the NIV device. Additional high-efficiency particulate arrestance (HEPA) filter on the exhalation output of the mechanical ventilator J o u r n a l P r e -p r o o f was also used (Righetti et al., 2020; Kaur et al., 2020) . The patients were ventilated with positive end-expiratory pressure (PEEP) ≥8 cmH2O, support pressure for a tidal volume (TV) ≤8 mL/kg of the predicted weight, and the fraction of inspired oxygen (FiO2) to maintain peripheral oxygen saturation (SpO2) >92%. A face mask or total face mask should be used during the application of NIV, but for applications longer than 2 hours the use of total face mask was recommended in order to reduce the risk of skin breakdown (Yamaguti et al., 2014) . Patients wearing a face mask used a protective pad on the nasal area. For HFNC, a flow rate of 40 to 50 L/min should be maintained, and FiO2 to maintain SpO2 >92% should be started (Righetti et al., 2020) . NIV or HFNC was applied to subjects admitted to the critical care unit who presented SpO2 < 93% despite oxygen delivered through a nasal cannula (oxygen flow >6 L/min), venturi mask (FiO2 ∼30%), or oxygen bag (FiO2 ∼100%) and signs of respiratory distress (Righetti et al., 2020 Laboratory assessments included blood cell counts, C-reactive protein (CRP), Ddimer level, glutamate-pyruvate transaminase (GPT), glutamate-oxalacetate transaminase (GOT), total bilirubin (TB), plasma potassium and sodium levels.

Data collected from the NIV and HFNC were modality and ventilatory settings for NIV and flow rate for HFNC. To assess the effects of NIV and HFNC on AHRF induced by COVID-19, respiratory rate, SpO2, and ROX index were collected before, during, and up to 1 hour after treatment. ROX index was calculated using the formula (SpO2/FiO2)/respiratory rate. Also, adverse events from the application of NIV and HFNC, and outcomes of mortality and hospital discharge were collected.

The physiotherapists directly involved in assisting COVID-19 patients and non-COVID-19 ones were monitored. Physiotherapists with fever or respiratory symptoms underwent nasal and pharyngeal swab specimens collection and performed the real-time reverse-transcription-polymerase-chain-reaction (RT-PCR) against SARS-CoV-2.

Data were assessed for normality using the Shapiro-Wilk test. Parametric variables are presented as mean ± standard deviation and nonparametric variables as median and interquartile range. Categorical data are presented as the absolute (n) and

relative frequency (%), using χ2 or Fisher's exact probability tests. Comparison between patients who received NIV and HFNC treatment were analyzed using the t-test, Mann-Whitney test, and the Wilcoxon signed-rank test as appropriate. For comparison before, during, and after NIV or HFNC treatment we used the One-way Repeated Measure ANOVA test. Statistical significance was indicated by a P value of less than .05.

Between March 2020 and April 2020, 138 spontaneous breathing patients with COVID-19 and hospitalized in the critical care unit were considered. We excluded 101 patients that received only oxygen therapy and 37 patients were included and their data analyzed. From the included patients 10 patients died. Figure 1 illustrates the patients' allocation to ventilatory support and clinical outcome. 

HFNC was used on the majority of patients. For the NIV application, the most used interface was the face mask. The mean of the pressure support used in the NIV was 8.2 ± 4.8 cmH2O, positive end-expiratory pressure (PEEP) was 9.3 ± 3.0 cmH2O with a fraction of inspired oxygen (FiO2) of 38.2 ± 20.8%. The mean of the flow used in the HFNC was 45.2 ± 6.5 L/min with FiO2 of 52.0 ± 17.2% (Table 2) .

The time of application with the device was longer in the group that was treated with HFNC compared to the group that received treatment with NIV (P<0.05) (Figure 2A ).

SpO2 increased during NIV treatment. However, this increase of SpO2 was not maintained after treatment interruption (P<0.05). There was no difference in SpO2 during and after HFNC treatment (P=0.17) ( Figure 2B ). In addition, there was no difference in J o u r n a l P r e -p r o o f the respiratory rate ( Figure 2C) 

The adverse events that occurred during treatment with NIV were 1 (7.14%) bronchoaspiration and 1 (7.14%) pressure ulcer outside the face region. In the treatment with HFNC, 3 (13%) respiratory instabilities were registered, but none required urgent endotracheal intubation and 5 (21.7%) pressure ulcers outside the face region. All adverse events occurred in different patients. patients with positive test RT-PCR in our hospital was 11.9% (Table 3 ). All showed mild symptoms of the disease and none required hospitalization. All infected physiotherapists recovered well.

The present study showed that the majority of patients were treated with HFNC.

SpO2 increased during NIV treatment. However, this increase of SpO2 was not maintained after treatment interruption. There was no difference in SpO2 and respiratory rate after NIV and HFNC treatment compared to baseline. Critical care unit and hospital length of stay were not different between the groups. There was no difference in the mortality rate and endotracheal intubation for NIV and HFNC treatment. Two adverse events occurred during treatment with NIV and eight occurred during treatment with HFNC. There were no differences in the rates of physiotherapists who tested positive for SARS-CoV-2 in the critical care unit dedicated to the assistance of patients with COVID-19 compared to the critical care unit non-dedicated to COVID-19.

The population consisted mostly of men (70.3%) and older individuals. The median age of the patients admitted to the ICU was 68 ±18.5 years old. A previous study showed that male gender and older age are associated with severe COVID-19 (Rapp et al., 2020) . However, showed that the median age of the patients admitted to the intensive care unit is the same as the median age of all the positive Italian cases with COVID-19, suggesting that the older age alone is not a risk factor for admission to the critical care unit. In the present study, 86% of patients had at least one comorbidity and 62.1% had three or more comorbidities, much higher than in others (Huang et al., 2020; Guan et al., 2020; Wang et al., 2020) . Similar to other previous reports, hypertension was the most common comorbidity, followed by dyslipidemia, cardiovascular disorders, and diabetes (Guan et al., 2020; Wang et al., 2020) . These data show that we studied a population with risk factors for developing severe disease, such as age and comorbidities, similar to other hospital centers.

The success and time of therapy of non-invasive strategies also depend on tolerance and patient compliance. The present study showed a longer therapy time in the HFNC group compared to the NIV group. HFNC can provide both adequate heating and humidification, which helps to increase the humidity of the airway, maintain mucosal function, promote secretion clearance, avoid epithelial injury, and improve patient J o u r n a l P r e -p r o o f comfort and tolerance (Nishimura et al., 2016) . Intolerance to NIV can affect 20-25% of patients treated for hypoxemic ARF (Demoule et al., 2006) . In healthy subjects, low levels of humidification or the absence of any additional humidification system under NIV were associated with less comfort (Lellouche et al., 2009) . Therefore, the possibility of maintaining heating and humidification and the low claustrophobic interface of HFNC appear to be the factors that better patient tolerance for a longer duration of device (Roca et al., 2019; Mukhtar et al., 2021) . ROX at 4 h of starting HFNC ≥5.37 was significantly associated with a lower risk for intubation in COVID-19 hypoxemic respiratory failure in intensive care admitted patients from a retrospective single-center study (Zucman et al., 2020) . In the present study, ROX index increased in NIV and HFNC treatment increased during and after treatment, showing benefits from the NIV and HFNC treatment.

COVID-19 is a new disease and its pathophysiology is uncertain. Polak et al., (2020) reviewed 129 cases of published lung samples (either full/partial autopsy or lung resection) and identified three main histological patterns: epithelial (85%), with reactive epithelial changes and diffuse alveolar damage (DAD); vascular (59%) with microvascular damage, microthrombi, and acute fibrinous and organizing pneumonia;

and fibrotic (22%) with interstitial fibrosis. The low response in SpO2 and respiratory rate can be explained by the structural pulmonary changes that occur in this disease J o u r n a l P r e -p r o o f (Gattinoni et al., 2020; Grieco et al., 2020) . In the present study, the low response in SpO2 and the respiratory rate does not mean that HFNC and NIV cannot benefit these patients. Grieco et al. (2021) did not show differences in respiratory frequency in the HFNC intervention and the NIV in patients with COVID-19, but they did show a reduction in dyspnea symptoms.

The numbers of adverse events in the NIV and HFNC treatment were similar.

Nasal and facial skin breakdown caused by long-time NIV therapy is relatively common 11 and can also increase NIV intolerance (Nevalesi et al., 2000; Nevalesi et al., 2007) . Sun et al. (2019) showed that the skin breakdown was significantly more common in the NIV group compared to the HFNC treatment (20.9% vs 5.1%). However, the present study did not present any skin lesion records. These findings are the result of institutional guidelines for monitoring skin health and the interface for the NIV treatment (Yamaguti et al., 2014) . The most common adverse event reported was a pressure ulcer outside the face region. Li et al. (2016) showed that patients with pressure ulcers had a longer length of stay than patients without pressure ulcer stay, especially those with periods of ICU stay above 7 days.

The need for invasive mechanical ventilation in these patients with COVID-19 was higher than that recently reported for other ICU units. Previous studies show different results of intubation needs: 88% in Italy , 71% in Washington State (USA) (Arentz et al., 2020) , and 47% in Wuhan (China) . The need for invasive mechanical ventilation in these patients with severe COVID-19 was also higher compared with data reported by the Chinese study and lower compared with data reported by other studies. In the present study, the use of noninvasive ventilatory support prevented the need for intubation in 35.1% of the patients.

Corroborating with our study, Franco et al. (2020) showed that three modes of ventilatory support (NIV, CPAP, and HFNC) had a similar impact and mortality outcome, both on intubation rate and length of stay. On the other hand, our mortality results are J o u r n a l P r e -p r o o f lower than those presented by Bhatraju et al. (2020) , which showed a very high mortality rate both with NIV and HFNC (80% and 52%, respectively). However, it has to be noted that HFNC was usually applied in less severe patients compared with NIV. This may reflect the decision of the clinicians and physiotherapists to start NIV in cases in which they judged that applying a relatively high level of PEEP was more appropriate.

The use of NIV and HFNC is described in the literature as a potential aerosol generator and with the risk of infection of healthcare professionals (Agarwal et al., 2020; Ferioli et al., 2020) . However, the World Health Organization (2020) and other guidelines developed by experts from different countries have used NIV and HFNC in the treatment of AHRF that occurred in COVID-19 (Lazzeri et al., 2020; Righetti et al., 2020; Alhazzani et al., 2020) . For the application of these devices to be safer, several protective actions were implemented, mainly the placement of a filter in the ventilation circuit of the patients (Lucchini et al., 2020) . Conventional heat and moisture exchange filter (HME) may allow up to 60% of medical aerosol to pass through (Ari et al., 2016) so only the use of HME with an electrostatic bacterial filter (HMEF) should be considered to reduce exhaled pathogens from intubated patients during mechanical ventilation. Therefore, in our hospital, the HMEF was adopted to be used in NIV devices, but not for HFNC. Franco et al. (2020) ratio of these patients, and the level of patient discomfort was not assessed, and this factor could limit the efficacy of these techniques. Third, we do not monitor the access to different environments by each professional outside the hospital. Finally, another physiological study with a longer duration of the treatment and also a larger randomized controlled study of NIV and HFNC in COVID-19 patients with acute hypoxemic respiratory failure are needed to confirm our results and to further elucidate the efficacy of NIV and HFNC in this patient population.

The application of NIV and HFNC in the critical care unit is feasible and associated with favorable outcomes. In addition, there was no increase in the infection rate of physiotherapists with SARS-CoV-2.

We thank the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, number 18/16832-9) and Hospital Sírio-Libanês.

The data used to support the findings of this study are included within the article

The authors report no conflict of interest in this research. J o u r n a l P r e -p r o o f 

Flow (L/min), mean ± SD 45.2 ± 6.5 

High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Secondhand aerosol exposure during mechanical ventilation with and without expiratory filters: an in-vitro study

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Benefits and risks of success or failure of noninvasive ventilation

Use of high-flow nasal cannula and noninvasive ventilation in patients with COVID-19: A multicenter observational study

Protecting healthcare workers from SARS-CoV-2 infection: practical indications

Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Region

Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with hypoxemic respiratory failure: A systematic review

Water content of delivered gases during non-invasive ventilation in healthy subjects

The relationship among pressure ulcer risk factors, incidence and nursing documentation in hospital-acquired pressure ulcer patients in intensive care units

Procedures to minimize viral diffusion in the intensive care unit during the COVID-19 pandemic

Admission SpO2 and ROX index predict outcome in patients with COVID-19

Comparison of High-Flow Nasal Cannula and Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Due to Severe COVID-19 Pneumonia

COVID-19) treatment guidelines: clinical presentation

Non-invasive ventilation in chronic obstructive pulmonary disease subjects: helmet versus facial mask

Physiologic evaluation of noninvasive mechanical ventilation delivered with three types of masks in subjects with chronic hypercapnic respiratory failure

High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects

A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression

Male Sex, Severe Obesity, Older Age, and Chronic Kidney Disease Are Associated With

Physiotherapy Care of Patients with Coronavirus Disease 2019 (COVID-19) -A Brazilian Experience

An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy

Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

High-flow nasal oxygen versus noninvasive ventilation for hypoxemic respiratory failure: Do we know enough?

High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acutemoderate hypercapnic respiratory failure: an observational cohort study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

No evidence of increasing COVID-19 in health care workers after implementation of high flow nasal cannula: A safety evaluation

World Health Organization. Clinical management of COVID-19

Treatment-related risk factors for development of skin breakdown in subjects with acute respiratory failure undergoing noninvasive ventilation or CPAP

Clinical Course and Outcomes of Critically Ill Patients With SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study

Prediction of outcome of nasal high flow use during COVID-19-related acute hypoxemic respiratory failure

We thank the rehabilitation service team of the Hospital Sírio-Libanês.J o u r n a l P r e -p r o o f